XML 66 R51.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt - Long-Term Debt from Royalty-Bearing Instrument-December 2012 Financing - Additional Information (Detail) - USD ($)
1 Months Ended 12 Months Ended
Dec. 06, 2012
Feb. 27, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Debt Disclosure [Line Items]          
Gain (loss) on change in fair value of derivative liabilities         $ 8,170,000
Long-term debt from royalty-bearing instrument, carrying amount net of unamortized discount     $ 79,710,000 $ 92,403,000  
Interest expense, non-cash     2,183,000 2,332,000 $ 7,783,000
CPPIB          
Debt Disclosure [Line Items]          
Maximum repayment of future revenue and receivables     88,600,000    
Repayment under agreement     $ 20,500,000    
CPPIB | Subsequent Event          
Debt Disclosure [Line Items]          
Repayment under agreement   $ 7,700,000      
CPPIB | Vascepa          
Debt Disclosure [Line Items]          
Debt and future repayments percentage of net revenues     10.00%    
BioPharma Debt          
Debt Disclosure [Line Items]          
Amount received at the closing of the agreement $ 100,000,000        
Maximum repayment of future revenue and receivables 150,000,000        
Royalty-Bearing Debt          
Debt Disclosure [Line Items]          
Fair value of embedded derivative liability $ 14,600,000        
Gain (loss) on change in fair value of derivative liabilities     $ 0 0  
Long-term debt from royalty-bearing instrument, carrying amount net of unamortized discount     79,700,000 92,400,000  
Royalty-Bearing Debt | Cash          
Debt Disclosure [Line Items]          
Interest expense, contractual coupon interest     5,600,000 6,400,000  
Royalty-Bearing Debt | Non Cash          
Debt Disclosure [Line Items]          
Interest expense, non-cash     $ 2,000,000 $ 2,100,000